GRM7 polymorphisms and risk of schizophrenia in Iranian population
- 15 Downloads
The role of metabotropic glutamate receptors in the pathogenesis of schizophrenia or response to antipsychotic treatment has been proposed previously. The aim of the current study was to investigate the associations between two intronic variants within GRM7 gene (rs6782011 and rs779867) and schizophrenia in Iranian population. These two single nucleotide polymorphisms (SNPs) were genotyped in 273 schizophrenic patients and 300 age and sex-matched normal controls. The frequency of A allele of the rs779867 was significantly lower in the schizophrenic patients compared with healthy subjects (OR (95% CI) = 0.71 (0.56–0.89), adjusted P value = 0.008). This SNP was associated with schizophrenia in co-dominant and dominant models (adjusted P values of 0.03 and 0.02 respectively). However, there was no difference in allele and genotype frequencies of the rs6782011 SNP between cases and controls. Consequently, the results of current study further highlight the participation of GRM7 in the pathogenesis of schizophrenia.
KeywordsGRM7 Polymorphism Schizophrenia
The current study was supported by a grant from Shahid Beheshti University of Medical Sciences.
Compliance with ethical standards
Conflict of interest
The authors declare they have no conflict of interest.
- Association, D.-A. P. 2013. Diagnostic and statistical manual of mental disorders. Arlington: American Psychiatric PublishingGoogle Scholar
- Bertram M, Berube N, Hang-Swanson X, Ran Q, Leung J, Bryce S, Spurgers K, Bick R, Baldini A, Ning Y (1999) Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genes. Mol Cell Biol 19:1479–1485CrossRefGoogle Scholar
- Drahl C (2008) Rethinking schizophrenia. Chem Eng News 86:38–40Google Scholar
- Fell MJ, Svensson KA, Johnson BG, Schoepp DD (2008) Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (−)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 326:209–217CrossRefGoogle Scholar
- Irmansyah, Schwab SG, Heriani, Handoko HY, Kusumawardhani A, Widyawati I, Amir N, Nasrun MWS, Holmans P, Knapp M, Wildenauer DB (2008) Genome-wide scan in 124 Indonesian sib-pair families with schizophrenia reveals genome-wide significant linkage to a locus on chromosome 3p26-21. Am J Med Genet B Neuropsychiatr Genet 147B:1245–1252CrossRefGoogle Scholar
- Jalan-Sakrikar N, Field JR, Klar R, Mattmann ME, Gregory KJ, Zamorano R, Engers DW, Bollinger SR, Weaver CD, Days EL, Lewis LM, Utley TJ, Hurtado M, Rigault D, Acher F, Walker AG, Melancon BJ, Wood MR, Lindsley CW, Conn PJ, Xiang ZX, Hopkins CR, Niswender CM (2014) Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7. ACS Chem Neurosci 5:1221–1237CrossRefGoogle Scholar
- Li W, Ju K, Li Z, He K, Chen J, Wang Q, Yang B, An L, Feng G, Sun W, Zhou J, Zhang S, Song P, Khan RAW, Ji W, Shi Y (2016) Significant association of GRM7 and GRM8 genes with schizophrenia and major depressive disorder in the Han Chinese population. Eur Neuropsychopharmacol 26:136–146CrossRefGoogle Scholar
- Lu, Y., Quan, C., Chen, H., Bo, X. & Zhang, C. 2016. 3DSNP: a database for linking human noncoding SNPs to their three-dimensional interacting genes. Nucleic acids research , gkw1022Google Scholar
- Ohtsuki T, Koga M, Ishiguro H, Horiuchi Y, Arai M, Niizato K, Itokawa M, Inada T, Iwata N, Iritani S, Ozaki N, Kunugi H, Ujike H, Watanabe Y, Someya T, Arinami T (2008) A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophr Res 101:9–16CrossRefGoogle Scholar
- Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102–1107CrossRefGoogle Scholar